Standout Papers

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanc... 2012 2026 2016 2021 4.8k
  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial (2015)
    Roy S. Herbst, Paul Baas et al. The Lancet
  2. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung (2012)
    Ji‐Youn Han, Keunchil Park et al. Journal of Clinical Oncology
  3. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study (2016)
    Glenwood Goss, Chun‐Ming Tsai et al. The Lancet Oncology
  4. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3) (2018)
    Yi‐Long Wu, Myung‐Ju Ahn et al. Journal of Clinical Oncology
  5. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study (2020)
    Lecia V. Sequist, Ji‐Youn Han et al. The Lancet Oncology
  6. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC (2021)
    Roy S. Herbst, Edward B. Garon et al. Journal of Thoracic Oncology
  7. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON (2022)
    Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery
  8. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial (2023)
    Juliann Chmielecki, Tony Mok et al. Nature Communications

Immediate Impact

8 by Nobel laureates 3 from Science/Nature 118 standout
Sub-graph 1 of 15

Citing Papers

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
2023 Standout
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
2023 Standout
23 intermediate papers

Works of Ji‐Youn Han being referenced

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
2020
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
2018 Standout
and 18 more

Author Peers

Author Last Decade Papers Cites
Ji‐Youn Han 8002 9442 2992 255 12.8k
Vassiliki A. Papadimitrakopoulou 7215 7561 3996 222 12.3k
Isamu Okamoto 9223 9325 3996 380 13.6k
Justin F. Gainor 6358 6392 3223 235 10.1k
Katsuyuki Hotta 8489 10920 2044 286 13.7k
Balázs Halmos 7435 7884 4826 266 12.4k
Rodryg Ramlau 8892 8701 3074 238 12.5k
Jin Seok Ahn 7536 8356 3111 440 13.0k
Scott Gettinger 6665 9980 2783 255 12.8k
Maya Gottfried 7572 10411 1889 155 12.9k
Toyoaki Hida 8379 7963 3920 280 13.2k

All Works

Loading papers...

Rankless by CCL
2026